SAN FRANCISCO, March 4, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it has entered into a securities purchase agreement with TCGX, an institutional accredited investor, to sell securities in a private placement financing (the “PIPE”) for gross…Read More
“I couldn’t be more pleased with Bill Beyer’s contributions to Tubi as interim CFO during the hypergrowth stage of the company. His experienced management acumen, strategic insights, financial expertise allowed us to be super-selective in our CFO search. He owned a tremendous debt financing providing Tubi with great optionality for further financings as well as the necessary resources to fund our growth. I wouldn’t hesitate to bring Bill and FLG in again on Tubi’s behalf.”